Отдаленные результаты иммуносупрессивной терапии у больных апластической анемией (опыт одного центра)

Source: Клиническая онкогематология, Vol 16, Iss 3 (2024)

Subject Terms: апластическая анемия, ПНГ-клон, беременность, клональная эволюция, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, осложнения, иммуносупрессивная терапия, ремиссия, RC254-282, 3. Good health

Access URL: https://doaj.org/article/0d39dcb20efc41fa8f4758117d18d9cf

Evolution of Views on Pathogenesis and Treatment of Immunoglobulin A-Nephropathy: What’s New Today? ; Эволюция взглядов на патогенез и лечение иммуноглобулин А-нефропатии: что нового сегодня?

Authors: O. N. Sigitova, E. V. Efremova, A. R. Bogdanova, M. I. Khasanova, О. Н. Сигитова, Е. В. Ефремова, А. Р. Богданова, М. И. Хасанова

Contributors: The authors declare no funding for this study., Авторы заявляют об отсутствии финансирования.

Source: The Russian Archives of Internal Medicine; Том 15, № 5 (2025); 325-335 ; Архивъ внутренней медицины; Том 15, № 5 (2025); 325-335 ; 2411-6564 ; 2226-6704

Subject Terms: ингибиторы натрий-глюкозного котранспортера 2-го типа, immunosuppressive therapy, renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter type 2 inhibitors, иммуносупрессивная терапия, ингибиторы ренин-ангиотензин-альдостероновой системы

File Description: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/2077/1443; Schena F.P., Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin. Nephrol. 2018; 38(5):435-42. doi:10.1016/j.semnephrol.2018.05.013.; Pitcher D., Braddon F., Hendry B. et al. Long-term outcomes in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 2023; 18:727-38. https://doi.org/10.2215/CJN.0000000000000135.; Moriyama T., Tanaka K., Iwasaki C. et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014; 9:e91756. doi:10.1371/journal.pone.0091756; Добронравов В.А., Мужецкая Т.О., Лин Д.И. и др. Иммуноглобулин А-нефропатия в российской популяции: клинико-морфологическая презентация и отдаленный прогноз. Нефрология. 2019; 23(6):45-60. doi:10.36485/1561-6274-2019-23-6-45-60.; Батюшин М.М., Бобкова И.Н., Ватазин А.В. и др. Гломерулярные болезни: иммуноглобулин А-нефропатия. Клинические рекомендации. 2021. [Электронный ресурс]. URL: https://rusnephrology.org/wp-content/uploads/2021/04/iga_060421-1.pdf. (дата обращения: 29.01.2025).; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100(4S):1-276.; Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13(1):142-8.; Wheeler D.C., Toto R.D., Stefánsson B.V., et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021; 100(1): 215-24. doi:10.1016/j.kint.2021.03.033.; Herrington W.G., Staplin N., Wanner C., et al., EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2022 Nov 4. doi:10.1056/NEJMoa2204233.; McGrogan A., Franssen C.F., de Vries C.S. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011; 26:414-430. doi:10.1093/ndt/gfq665/; Yeo S.C., Goh S.M., Barratt J. Is immunoglobulin A nephropathy different in different ethnic populations? Nephrology (Carlton). 2019; 24(9):885-895. doi:10.1111/nep.13592.; Lai, K.N., Tang, S.C.W., Schena, F.P., et. al. IgA nephropathy. Nature Reviews Disease Primers. 2016; 2:16001. doi:10.1038/nrdp.2016.1.; Зубкин М.Л., Солдатов Д.А., Фролова Н.Ф. и др. Современные представления о патогенезе IgA-нефропатии. Нефрология и диализ. 2024; 26(1):35-54. doi:10.28996/2618-9801-2024-1-35-54.; Sallustio F., Curci C., Chaoul N. et al. High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrol Dial Transplant. 2021; 36(3):452-464. doi:10.1093/ndt/gfaa264.; He J.W., Zhou X.J., Hou P. et al. Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A Nephropathy. Front Cell Infect Microbiol. 2021; 11:652837. doi:10.3389/fcimb.2021.652837.; Zhao J., Bai M., Yang X. et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports. Renal. Failure. 2021; 43(1):928-933. doi:10.1080/0886022X.2021.1936038.; Gesualdo L., Di Leo V., Coppo R. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021; 43(5):657-668. doi:10.1007/s00281-021-00871-y.; Rehnberg J., Symreng A., Ludvigsson J.F. et al. Infl amatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study. J Am Soc Nephrol. 2021; 32(2):411-423. doi:10.1681/ASN.2020060848.; Kovács T., Kun L., Schmelczer M. et al. Do intestinal hyperpermeability and the related food antigens play a role in the progression of IgA nephropathy? I. Study of intestinal permeability. Am J Nephrol. 1996; 16(6):500-505. doi:10.1159/000169050.; Serena G., D’Avino P., Fasano A. Celiac Disease and Non-celiac Wheat Sensitivity: State of Art of Non-dietary Therapies. Front Nutr. 2020; 7:152. doi:10.3389/fnut.2020.00152.; Slavin S.F. IgA Nephropathy as the Initial Presentation of Celiac Disease in an Adolescent. Pediatrics. 2021; 148(4):e2021051332. doi:10.1542/peds.2021-051332.; Бобкова И.Н., Ватазин А.В., Ветчинникова О.Н. и др. Хроническая болезнь почек (ХБП). Клинические рекомендации. 2024. [Электронный ресурс]. URL: https://rusnephrology.org/wpcontent/uploads/2020/12/CKD_final.pdf. (дата обращения: 29.01.2025).; Шилов Е.М., Бобкова И.Н., Колина И.Б. и др. Клинические рекомендации по диагностике и лечению IgA-нефропатии. Нефрология. 2015; 19(6): 83-92.; Wu J., Hu Z., Wang Y. et al. Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy. Histopathology. 2021; 78(6):882-895. doi:10.1111/his.14318.; Khairwa A. Indian scenario of IgA nephropathy: a systematic review and meta-analysis. Afr. Health Sci. 2021; 21(1):159-165. doi:10.4314/ahs.v21i1.21-54.; Gleeson P.J., O’Shaughnessy M.M., Barratt J. IgA nephropathy in adults—treatment standard, Nephrology Dialysis Transplantation. 2023; 38(11):2464-2473. doi:10.1093/ndt/gfad146.; Trimarchi H., Barratt J., Cattran D.C. et al. IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. doi:10.1016/j.kint.2017.02.003.; Gharavi A.G., Yan Y., Scolari F. et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat. Genet. 2000; 26(3):354-357. doi:10.1038/81677.; Wakai K., Kawamura T., Endoh M. et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol. Dial. Transplant. 2006; 21:2800-2808. doi:10.1093/ndt/gfl342.; International IgAN Prediction Tool at biopsy — Adults calculator. 2019. [Электронный ресурс]. URL: https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-adults. (дата обращения: 29.01.2025).; Bartosik L.P., Lajoie G., Sugar L. et al. Predicting progression in IgA nephropathy. Am. J. Kidney Dis. 2001; 38:728-735. doi:10.1053/ajkd.2001.27689.; Moroni G., Longhi S., Quaglini S. et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol. Dial. Transplant. 2013; 28:1305-1314. doi:10.1093/ndt/gfs472.; Rovin B.H., Adler S.G., Barratt J. et al. Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases. Kidney Int. 2021; 100:753-779. doi:10.1016/j.kint.2021.05.015.; Patrick J. Gleeson, Michelle M. O’Shaughnessy, Jonathan Barratt. IgA nephropathy in adults — treatment standard. Nephrol. Dial. Transplant. 2023; 38:2464-2473. doi:10.1093/ndt/gfad146.; Praga M., Gutiérrez E., González E. et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J. Am. Soc. Nephrol. 2003; 14(6):1578-1583. doi:10.1097/01.asn.0000068460.37369.dc.; Zhao Y., Fan H., Bao B.Y. Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Iran J. Public Health. 2019; 48(9):1577-1588. doi:10.18502/ijph.v48i9.3014.; Сигитова О.Н. Лечение артериальной гипертензии у пациентов с хронической болезнью почек с позиции Европейских рекомендаций 2023 г. Казанский медицинский журнал. 2024; 105(4):607-621. doi:10.17816/KMJ626252.; Heerspink H.J.L., Stefansson B.V., Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020; 383:1436-1446. doi:10.1056/NEJMoa2024816.; Heather N. Reich and Jürgen Floege. Cl. J. Am. Soc. Nephrol. 2022; 17(8): 1243-1246. doi:10.2215/CJN.02710322.; The E-KCG, Herrington W.G., Staplin N. et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2023; 388:117-127. doi:10.1056/NEJMoa2204233.; EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol. Dial. Transplant. 2022; 37:1317-1329. doi:10.1093/ndt/gfac040.; Braunwald E. Gliflozins in the management of cardiovascular disease. N. Engl. J. Med. 2022; 386:2024-2034. doi:10.1056/NEJMra2115011.; Donadio J.V., Grande J.P., Bergstralh E.J. et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J. Am. Soc. Nephrol. 1999; 10(8):1772-1777. doi:10.1681/ASN.V1081772.; Hogg R.J., Lee J., Nardelli N. et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin. J. Am. Soc. Nephrol. 2006; 1(3):467-474. doi:10.2215/CJN.01020905.; Strippoli G.F., Manno C., Schena F.P. An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism. Am. J. Kidney Dis. 2003;41(6):1129–39. doi:10.1016/s0272-6386(03)00344-5.; Rehnberg J., Symreng A., Ludvigsson J.F. et al. Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish PopulationBased Cohort Study. J. Am. Soc. Nephrol. 2021; 32(2):411-423. doi:10.1681/ASN.2020060848.; Yang D., He L., Peng X. et al. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial. Ren. Fail. 2016; 38:242-248. doi:10.3109/0886022X.2015.1128251.; Pozzi C., Bolasco P.G., Fogazzi G.B. et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353:883-887. doi:10.1016/S0140-6736(98)03563-6.; Lv J., Zhang H., Wong M.G. et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017; 318:432-442. doi:10.1001/jama.2017.9362.; Lv J., Wong M.G., Hladunewich M.A. et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022; 327:1888-1898. doi:10.1001/jama.2022.5368.; Rauen T., Eitner F., Fitzner C. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 2015; 373:2225-2236. doi:10.1056/NEJMoa1415463.; Rauen T., Wied S., Fitzner C. et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020; 98:1044-1052. doi:10.1016/j.kint.2020.04.046.; Lv J., Zhang H., Chen Y. et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am. J. Kidney Dis. 2009; 53:26-32. doi:10.1053/j.ajkd.2008.07.029.; Han S., Yao T., Lu Y. et al. Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis. Front. Pharmacol. 2021; 11:539545. doi:10.3389/fphar.2020.539545.; Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017; 63(6):392-426. doi:10.14341/probl2017636392-426.; Barratt J., Lafayette R., Kristensen J. et al. NefIgArd Trial Investigators. Results from part A of the multi-center, doubleblind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023; 103(2):391-402. doi:10.1016/j.kint.2022.09.017.; Ma F., Yang X., Zhou M. et al. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide. J. Nephrol. 2020; 33(6):1241-1250. doi:10.1007/s40620-020-00752-x.; Liu L.J., Yang Y.Z., Shi S.F. et al. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am. J. Kidney Dis. 2019; 74(1):15-22. doi:10.1053/j.ajkd.2019.01.026.; Hou F.F., Xie D., Wang J. et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw. Open. 2023; 6(2):e2254054. doi:10.1001/jamanetworkopen.2022.54054.; Hernández-Rodríguez J., Carbonell C., Mirón-Canelo J.A. et al. Rituximab treatment for IgA vasculitis: A systematic review. Autoimmun. Rev. 2020; 19(4):102490. doi:10.1016/j.autrev.2020.102490.; Gleeson P.J., O’Shaughnessy M.M. and Barratt J. IgA nephropathy in adults—treatment standard. Nephrol Dial Transplant, 2023, 38, 2464–2473 https://doi.org/10.1093/ndt/gfad146 Downloaded from https://academic.oup.com/ndt/article/38/11/2464/7221084 by guest on 25 December 2024; https://www.medarhive.ru/jour/article/view/2077

Availability: https://www.medarhive.ru/jour/article/view/2077
https://doi.org/10.20514/2226-6704-2025-15-5-325-335

Comorbid infections in patients with ANCA-associated systemic vasculitis: a prospective cohort study ; Коморбидные инфекции у пациентов с АНЦА-ассоциированными системными васкулитами: проспективное когортное исследование

Authors: M. A. Litvinova, N. M. Bulanov, P. I. Novikov, J. Zhao, D. Munblit, S. V. Moiseev, М. А. Литвинова, Н. М. Буланов, П. И. Новиков, Ц. Чжао, Д. Б. Мунблит, С. В. Моисеев С.В

Source: Modern Rheumatology Journal; Том 19, № 2 (2025); 50-57 ; Современная ревматология; Том 19, № 2 (2025); 50-57 ; 2310-158X ; 1996-7012

Subject Terms: сепсис, immunosuppressive therapy, infections, sepsis, иммуносупрессивная терапия, инфекции

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1739/1583; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi:10.1002/art.37715.; Новиков ПИ, Семенкова ЕН, Моисе ев СВ. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013;22(1):70-4.; Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010 Jun;69(6): 1036-43. doi:10.1136/ard.2009.109389. Epub 2009 Jul 1.; Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011 Mar; 70(3):488-94. doi:10.1136/ard.2010.137778. Epub 2010 Nov 24.; Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi:10.1001/jama.2016.0287.; Gialouri CG, Chalkia A, Koutsianas C, et al. Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study. Rheumatology (Oxford). 2024 Aug 6:keae409. doi:10.1093/rheumatology/keae409. Online ahead of print.; Thomas K, Argyriou E, Kapsala N, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Res Ther. 2021 Mar 20;23(1):90. doi:10.1186/s13075-021-02452-8.; Weidanz F, Day CJ, Hewins P, et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis. 2007 Jul;50(1):36-46. doi:10.1053/j.ajkd.2007.04.018.; Rathmann J, Jayne D, Segelmark M, et al. Incidence and predictors of severe infections in ANCA-associated vasculitis: a populationbased cohort study. Rheumatology (Oxford). 2021 Jun 18;60(6):2745-2754. doi:10.1093/rheumatology/keaa699.; Thery-Casari C, Euvrard R, Mainbourg S, et al. Severe infections in patients with antineutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A metaanalysis. Autoimmun Rev. 2020 May;19(5): 102505. doi:10.1016/j.autrev.2020.102505. Epub 2020 Mar 12.; Obrisca B, Vornicu A, Jurubita R, et al. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol. 2021 Aug;40(8):3285-3297. doi:10.1007/s10067-021-05646-2. Epub 2021 Feb 17.; Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi:10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.; Landewe RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022 Dec;81(12): 1628-1639. doi:10.1136/annrheumdis-2021-222006. Epub 2022 Feb 23.; Буланов НМ, Новиков ПИ, Гуляев СВ и др. Переносимость вакцины Гам-КОВИД-Вак (Спутник V) у взрослых пациентов с иммуновоспалительными ревматическими заболеваниями. Клиническая фармакология и терапия. 2021; 30(4):23-28.; Литвинова МА, Буланов НМ, Нови ков ПИ и др. Применение тиксагевимаба и цилгавимаба (Эвушелд) для доконтактной профилактики COVID-19 у пациентов с АНЦА-ассоциированными васкулитами: проспективное исследование. Клиническая фармакология и терапия. 2023;32(4): 24-29.; Белов БС, Тарасова ГМ, Буханова ДВ. Коморбидные инфекции при ревматических заболеваниях. Антибиотики и химиотерапия. 2019;64(1-2):50-57.; Smith R. Complications of therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii74-iii78. doi:10.1093/rheumatology/kez618. PMID: 31967652.; Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003 Apr;41(4):776-84. doi:10.1016/s0272-6386(03)00025-8.; Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018 Jun 14;19(1):138. doi:10.1186/s12882-018-0933-2.; Goupil R, Brachemi S, Nadeau-Fredet te AC, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2013 Mar;8(3):416-23. doi:10.2215/CJN.07300712. Epub 2012 Dec 6.; Nettleton E, Sattui SE, Wallace Z, Putman M. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide. Arthritis Care Res (Hoboken). 2024 Feb;76(2):288-294. doi:10.1002/acr.25222. Epub 2023 Oct 28.; Nakaya I, Sada KE, Harigai M, et al. Chemoprophylaxis against Pneumocystis jirovecii pneumonia in Japanese patients with ANCA-associated vasculitis: An observational study. Mod Rheumatol. 2023 Nov 1;33(6): 1137-1144. doi:10.1093/mr/roac124.; Haris A, Polner K, Aranyi J, et al. Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis. BMC Nephrol. 2017 Feb 23;18(1):76. doi:10.1186/s12882-017-0491-z.; Haris A, Polner K, Aranyi J, Braunitzer H, Kaszas I. Incidence and clinical predictors of infections in patients treated with severe systemic ANCA-associated vasculitis. Physiol Int. 2021 Mar 25. doi:10.1556/2060.2021.00006. Online ahead of print.; Odler B, Riedl R, Gauckler P, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023 May;82(5):681-687. doi:10.1136/ard-2022-223401. Epub 2023 Jan 26.; Kronbichler A, Kerschbaum J, Gopalu ni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutro phil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018 Oct;77(10):1440-1447. doi:10.1136/annrheumdis-2017-212861. Epub 2018 Jun 27.; Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi:10.1111/eci.12410; Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658-63. doi:10.1136/ard.2008.088302. Epub 2008 May 26.; de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19; 150(10):670-80. doi:10.7326/0003-4819-150-10-200905190-00004.; Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011 Aug;63(8):2209-14. doi:10.1002/art.30427.; Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century – a disease of older patients. Rheumatology (Oxford). 2005 Apr;44(4):495-501. doi:10.1093/rheumatology/keh522. Epub 2004 Dec 21.; Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021 Jun 1;325(21):2178-2187. doi:10.1001/jama.2021.6615.; Walsh M, Merkel PA, Peh CA, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-631. doi:10.1056/NEJMoa1803537.; Hellmich B, Sanchez-Alamo B, Schir mer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi:10.1136/ard-2022-223764.; Захарова ЕВ, Буланов НМ. Клинические практические рекомендации KDIGO 2024 по ведению васкулита, ассоциированного с антителами к цитоплазме нейтрофилов (АНЦА). Нефрология и диализ. 2024;26(4):397-434.

Availability: https://mrj.ima-press.net/mrj/article/view/1739
https://doi.org/10.14412/1996-7012-2025-2-50-57

Клональная эволюция апластической анемии (краткий обзор литературы и описание собственного клинического наблюдения)

Source: Клиническая онкогематология, Vol 15, Iss 3 (2022)

Subject Terms: апластическая анемия, 03 medical and health sciences, 0302 clinical medicine, гаплоидентичная трансплантация гемопоэтических стволовых клеток, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, миелодиспластический синдром, пароксизмальная ночная гемоглобинурия, иммуносупрессивная терапия, RC254-282, 3. Good health

Access URL: https://doaj.org/article/208feaa93c7d44fc95edd2cf2f842ec4

ОСОБЕННОСТИ ТЕЧЕНИЯ НЕФРОТИЧЕСКОГО СИНДРОМА У ДЕТЕЙ РАЗЛИЧНОГО ВОЗРАСТА И ЕГО КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ У ДЕТЕЙ АНДИЖАНСКОЙ ОБЛАСТИ

Authors: Нурматова, О.A.

Subject Terms: нефропатии, Гломерулонефрит, нефротический синдром, иммуносупрессивная терапия

Future of Solid Organ Transplantation: Organ-Specific Tolerance

Authors: Yusuf Ercin Sonmez

Source: Počki, Vol 10, Iss 3, Pp 130-136 (2021)
KIDNEYS; Vol. 10 No. 3 (2021); 130-136
Почки-Počki; Том 10 № 3 (2021); 130-136
Нирки-Počki; Том 10 № 3 (2021); 130-136

Subject Terms: 03 medical and health sciences, трансплантация органов, иммуносупрессивная терапия, отторжение, иммунная толерантность, регуляторные клетки, химеризм, обзор, 0302 clinical medicine, трансплантація органів, імуносупресивна терапія, відторгнення, імунна толерантність, регуляторні клітини, химеризм, огляд, RC870-923, organ transplantation, immunosuppressive therapy, rejection, immune tolerance, regulatory cells, chimerism, review, Diseases of the genitourinary system. Urology, 3. Good health

File Description: application/pdf

Access URL: https://doaj.org/article/4bbaf392193c41ee8e0e15a08f395a4e
http://kidneys.zaslavsky.com.ua/article/view/239589

ОСОБЕННОСТИ ТЕЧЕНИЯ НЕФРОТИЧЕСКОГО СИНДРОМА У ДЕТЕЙ РАЗЛИЧНОГО ВОЗРАСТА И ЕГО КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ У ДЕТЕЙ АНДИЖАНСКОЙ ОБЛАСТИ

Authors: Ганиева, М.Ш., Нурматова, О.A., Хайдарова, Л.Р., Болтабоева, М.М.

Subject Terms: Гломерулонефрит, нефротический синдром, нефропатии, иммуносупрессивная терапия

Relation: https://zenodo.org/records/10829216; oai:zenodo.org:10829216; https://doi.org/10.5281/zenodo.10829216

Availability: https://doi.org/10.5281/zenodo.10829216
https://zenodo.org/records/10829216

Polypharmacy, therapeutic inertia, and adherence of heart recipients to drug therapy ; Полипрагмазия, терапевтическая инертность и приверженность реципиентов сердца к медикаментозной терапии

Authors: I. I. Muminov, A. O. Shevchenko, V. N. Poptsov, N. N. Koloskova, A. A. Yusova, S. A. Sakhovsky, D. D. Uvarova, И. И. Муминов, А. О. Шевченко, В. П. Попцов, Н. Н. Колоскова, А. А. Юсова, С. А. Саховский, Д. Д. Уварова

Source: Russian Journal of Transplantology and Artificial Organs; Том 26, № 4 (2024); 122-132 ; Вестник трансплантологии и искусственных органов; Том 26, № 4 (2024); 122-132 ; 1995-1191

Subject Terms: амбулаторное наблюдение, polypharmacy, comorbidity, immunosuppressive therapy, outpatient, полипрогмазия, коморбидность, иммуносупрессивная терапия

File Description: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/1816/1709; Трансплантология: итоги и перспективы. Том XIII. 2021 год / Под ред. С.В. Готье. М.–Тверь: Триада, 2022: 416.; Муминов ИИ, Колоскова НН, Попцов ВН, Захаревич ВМ, Можейко НП, Саховский СА, Шевченко АО. Опыт амбулаторного наблюдения реципиентов после трансплантации сердца в НМИЦ ТИО имени академика В.И. Шумакова. Вестник трансплантологии и искусственных органов. 2023; 25 (3): 68–75. https://doi.org/10.15825/1995-1191-2023-3-68-75.; Готье СВ, Шевченко АО, Кормер АЯ, Попцов ВН, Шевченко ОП. Перспективы улучшения отдаленных результатов трансплантации сердца. Вестник трансплантологии и искусственных органов. 2014; 16 (3): 23–30. https://doi.org/10.15825/19951191-2014-3-23-30.; Колоскова НН, Никитина ЕА, Захаревич ВМ, Муминов ИИ, Кван ВС, Попцов ВН и др. Конверсия на эверолимус с целью сохранения функции почек при трансплантации сердца, персонализированный подход при выборе иммуносупрессивной терапии. Вестник трансплантологии и искусственных органов. 2018; 20 (3): 70–74. https://doi.org/10.15825/1995-11912018-3-70-74.; Wilkening GL, Brune S, Saenz PF, Vega LM, Kalich BA. Correlation between medication regimen complexity and quality of life in patients with heart failure. Res Social Adm Pharm. 2020 Oct; 16 (10): 1498–1501. doi:10.1016/j.sapharm.2020.01.003. Epub 2020 Jan 18. PMID: 32001156.; George J, Phun Y-T, Bailey MJ, Kong DC, Stewart K. Development and Validation of the Medication Regimen Complexity Index. Ann Pharmacother. 2004; 38 (9): 1369–1376. doi:10.1345/aph.1D479.; Hansen R, Seifeldin R, Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant Proc. 2007; 39: 1287–1300.; Abdelbary A, Kaddoura R, Balushi SA, Ahmed S, Galvez R, Ahmed A et al. Implications of the medication regimen complexity index score on hospital readmissions in elderly patients with heart failure: a retrospective cohort study. BMC Geriatr. 2023 Jun 19; 23 (1): 377. https://doi.org/10.1186/s12877-023-04062-2.; Harris SC, Jean SJ. Characterization of the medication regimen complexity index in high-utilizer, adult psychiatric patients. Ment Health Clin. 2020 Jul 2; 10 (4): 207–214. https://doi.org/10.9740/mhc.2020.07.207.; Masumoto S, Sato M, Momo K, Matsushita A, Suzuki K, Shimamura H et al. Development of medication regimen complexity index: Japanese version and application in elderly patients. Int J Clin Pharm. 2021 Aug; 43 (4): 858–863. doi:10.1007/s11096-020-01185-z. Epub 2020 Nov 2. PMID: 33136252.; Клинические рекомендации «Трансплантация сердца, наличие трансплантированного сердца, отмирание и отторжение трансплантата сердца», Российское трансплантологическое общество, одобрены Научно-практическим Советом Минздрава РФ в 2023.; Сычев ДА, Отделенов ВА, Краснова НМ, Ильина ЕС. Полипрагмазия: взгляд клинического фармаколога. Терапевтический архив. 2016; 88 (12): 94–102. doi:10.17116/terarkh2016881294-102.; Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct 10; 17 (1): 230. https://doi.org/10.1186/s12877-017-0621-2.; Gomis-Pastor M, Roig Mingell E, Mirabet Perez S, Brossa Loidi V, Lopez Lopez L, Diaz Bassons A et al. Multimorbidity and medication complexity: New challenges in heart transplantation. Clin Transplant. 2019 Oct; 33 (10): e13682. doi:10.1111/ctr.13682. Epub 2019 Aug 28. PMID: 31368585.; Kamila P, Smith SG, Patzer R, Wolf MS, Marina S. Medication regimen complexity in kidney and liver transplant recipients. Transplantation. 2014 Oct 15; 98 (7): e73–e74.; Colavecchia AC, Putney DR, Johnson ML, Aparasu RR. Discharge medication complexity and 30-day heart failure readmissions. Res Social Adm Pharm. 2017 Jul-Aug; 13 (4): 857–863. doi:10.1016/j.sapharm.2016.10.002. Epub 2016 Oct 8. PMID: 27771308.; https://journal.transpl.ru/vtio/article/view/1816

Availability: https://journal.transpl.ru/vtio/article/view/1816
https://doi.org/10.15825/1995-1191-2024-4-122-132

Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases? ; Является ли вакцинация против вирусного гепатита В безопасной и иммуногенной у пациентов с ревматическими заболеваниями?

Authors: G. I. Gridneva, B. S. Belov, E. S. Aronova, Г. И. Гриднева, Б. С. Белов, Е. С. Аронова

Contributors: The article was prepared as part of research work, government task №1021051503137-7. The investigation has not been sponsored., Статья подготовлена в рамках научно-исследовательской работы, № государственного задания 1021051503137-7. Исследование не имело спонсорской поддержки.

Source: Modern Rheumatology Journal; Том 18, № 5 (2024); 121-126 ; Современная ревматология; Том 18, № 5 (2024); 121-126 ; 2310-158X ; 1996-7012

Subject Terms: вакцинация, immunosuppressive therapy, antirheumatic drugs, chronic viral hepatitis B, screening, prevention, vaccination, иммуносупрессивная терапия, антиревматические препараты, хронический вирусный гепатит В, скрининг, профилактика

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1649/1528; https://mrj.ima-press.net/mrj/article/view/1649/1533; Min Y, Wei X, Xia X, et al. Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. Front Immunol. 2023 Mar 1;14:1141956. doi:10.3389/fimmu.2023.1141956. eCollection 2023.; Белов БС, Абдурахманов ДТ. Вирус гепатита В и ревматические болезни. Научно-практическая ревматология. 2020; 58(2):207-213.; Балабанова РМ. Ревматические заболевания и вирусная инфекция: есть ли связь? Современная ревматология. 2020;14(4): 98-102. doi:10.14412/1996-7012-2020-4-98–102; Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019 Feb;52(1):1-8. doi:10.1016/j.jmii.2017.10.002. Epub 2017 Nov 5.; Гриднева ГИ, Аронова ЕС, Белов БС. Хронический гепатит В у пациентов ревматологического стационара: проблемы скрининга и реактивации инфекции. Современная ревматология. 2023;17(5):67-72. doi:10.14412/1996-7012-2023-5-67-72.; Lin TC, Yoshida K, Tedeschi SK, et al. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018 May;70(5):724-731. doi:10.1002/acr.23346. Epub 2018 Apr 12.; Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019 Sep 19;5(2):e001041. doi:10.1136/rmdopen-2019-001041. eCollection 2019.; Zheng HW, Ouyang ZM, Pan J, et al. Hepatitis B virus infection status and clinical characteristics in patients with rheumatoid arthritis. Zhonghua Yi Xue Za Zhi. 2024 Jan 16;104(3):205-211. doi:10.3760/cma.j.cn112137-20230802-00132; Mahroum N, Watad A, Tiosano S, et al. Chronic hepatitis B viral infection among RA patients-a cross-sectional control study. Clin Rheumatol. 2019 May;38(5):1237-1241. doi:10.1007/s10067-019-04448-x. Epub 2019 Feb 8.; Capkin E, Yaz c A, Karkucak M, et al. Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int. 2023 Mar;43(3):523-531. doi:10.1007/s00296-022-05169-2. Epub 2022 Sep 5.; Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Diseasemodifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol. 2022 Jan;49(1):1-4. doi:10.3899/jrheum.211000. Epub 2021 Nov 1.; Canzoni M, Marignani M, Sorgi ML, et al. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms. 2020 Nov 16;8(11):1792. doi:10.3390/microorganisms8111792.; Министерство здравоохранения Российской Федерации. Клинические рекомендации. Острый гепатит В (ОГВ) у детей. https://cr.minzdrav.gov.ru/schema/488_2; Приказ от 6 декабря 2021 г. n 1122н об утверждении национального календаря профилактических прививок, календаря профилактических прививок по эпидемическим показаниям и порядка проведения профилактических прививок. https://normativ.kontur.ru/document?moduleId=1&documentId=410331.; Grotto I, Mandel Y, Ephros M, et al. Major adverse reactions to yeast-derived hepatitis B vaccines – a review. Vaccine. 1998 Feb; 16(4):329-34. doi:10.1016/s0264-410x(97)00214-4.; Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002 Jul;61(7):623-5. doi:10.1136/ard.61.7.623.; Toussirot E, Lohse A, Wendling D, Mougin C. Sjögren's syndrome occurring after hepatitis B vaccination. Arthritis Rheum. 2000 Sep;43(9):2139-40. doi:10.1002/1529-0131(200009)43:93.0.CO;2-3.; Saadoun D, Cacoub P, Mahoux D, et al. Vascularites postvaccinales: а propos de trois observations. Rev Med Interne. 2001 Feb; 22(2):172-6. doi:10.1016/s0248-8663(00)00307-6.; Fineschi S. Can recombinant anti-hepatitis B vaccine be a cause of systemic lupus erythematosus? Lupus. 2001;10(11):830. doi:10.1177/096120330101001114.; Grasland A, Le Maоtre F, Pouchot J, et al. Maladie de Still de l'adulte aprиs vaccination contre l'hйpatite A et B? Rev Med Interne. 1998 Feb;19(2):134-6. doi:10.1016/s0248-8663(97)83425-x.; Drucker Y, Prayson RA, Bagg A, Calabrese LH. Lymphocytic vasculitis presenting as diffuse subcutaneous edema after hepatitis B virus vaccine. J Clin Rheumatol. 1997 Jun;3(3): 158-61. doi:10.1097/00124743-199706000-00010.; Maillefert JF, Sibilia J, Toussirot E, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford). 1999 Oct;38(10):978-83. doi:10.1093/rheumatology/38.10.978.; Treves R, Lacoste L, Bontoux D, et al. Polyarthrite rhumatoide nodulaire erosive declenchee par une vaccination contre l'hepatite B. Presse Med. 1997 Apr 26;26(14):670.; Заяева А., Юнси СИ, Заусалина АИ и др. Аутоиммунный/воспалительный синдром, индуцированный адъювантами. Архивъ внутренней медицины. 2023;13(6): 405-412.; Nancy AL, Shoenfeld Y. Chronic fatigue syndrome with autoantibodies – the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev. 2008 Oct;8(1):52-5. doi:10.1016/j.autrev.2008.07.026. Epub 2008 Aug 24.; Shoenfeld Y, Agmon-Levin N. ‘ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011 Feb; 36(1):4-8. doi:10.1016/j.jaut.2010.07.003. Epub 2010 Aug 13.; Agmon-Levin N, Zafrir Y, Kivity S, et al. chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the 'autoimmune (auto-inflammatory) syndrome induced by adjuvants' (ASIA). Immunol Res. 2014 Dec; 60(2-3):376-83. doi:10.1007/s12026-014-8604-2.; WHO. Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023/. https://iris.who.int/bitstream/handle/10665/348966/9789240036963-eng.pdf?sequence=1; Ray P, Black S, Shinefield H, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine. 2011 Sep 2;29(38):6592-7. doi:10.1016/j.vaccine.2011.06.112. Epub 2011 Jul 16.; Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi:10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.; Rondaan C, Furer V, Heijstek MW, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019 Sep 9;5(2):e001035. doi:10.1136/rmdopen2019-001035. eCollection 2019.; Intongkam S, Samakarnthai P, Pakchotanon R, et al. Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy. J Clin Rheumatol. 2019 Dec;25(8):329-334. doi:10.1097/RHU.0000000000000877.; Erkek E, Ayaslioglu E, Erkek AB, et al. Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol. 2005 Oct;20(10):1508-11. doi:10.1111/j.1440-1746.2005.03903.x.; Haykir Solay A, Eser F. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccin Immunother. 2019;15(5):1177-1182. doi:10.1080/21645515.2019.1574151. Epub 2019 Mar 19.; Richi P, Alonso O, Martin MD, et al. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study. Clin Rheumatol. 2020 Sep;39(9):2751-2756. doi:10.1007/s10067-020-05042-2. Epub 2020 Apr 4.; Pratt PK Jr, David N, Weber HC, et al. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients with Inflammatory Bowel Disease on Infliximab Therapy. Inflamm Bowel Dis. 2018 Jan 18;24(2):380-386. doi:10.1093/ibd/izx001.; Romao VC, Avila-Ribeiro P, Goncalves MJ, et al. Hepatitis B vaccination associated with low response in patients with rheumatic diseases treated with biologics. RMD Open. 2023 Dec 6;9(4):e003597. doi:10.1136/rmdopen-2023-003597.; Schillie S, Harris A, Link-Gelles R, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR Morb Mortal Wkly Rep. 2018 Apr 20; 67(15):455-458. doi:10.15585/mmwr.mm6715a5.; Белов БС, Муравьева НВ. Современные представления о вакцинации больных ревматическими заболеваниями: взгляд экспертов ACR. Антибиотики и химиотерапия. 2023; (5–6):77-84.; Feuchtenberger M, Kleinert S, Schwab S, et al. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int. 2012 Jun;32(6):1533-9. doi:10.1007/s00296-011-1808-z. Epub 2011 Feb 15.; Kiltz U, Celik A, Tsiami S, et al. Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study. RMD Open. 2021 Apr;7(1):e001499. doi:10.1136/rmdopen-2020-001499.

Availability: https://mrj.ima-press.net/mrj/article/view/1649
https://doi.org/10.14412/1996-7012-2024-5-121-126

The successful treatment of refractory Crohn's disease by high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation: a clinical case ; Клинический случай успешного лечения рефрактерной болезни Крона методом высокодозной иммуносупрессивной терапии с аутологичной трансплантацией гемопоэтических стволовых клеток

Authors: Ganich E.G., Shchukina O.B., Polushin A.Y., Zalyalov Y.R., Tsynchenko A.A., Kamanin A.A., Kulikov A.N., Kulagin A.D., Bagnenko S.F.

Contributors: 1

Source: Almanac of Clinical Medicine; Vol 52, No 8 (2024); 446-453 ; Альманах клинической медицины; Vol 52, No 8 (2024); 446-453 ; 2587-9294 ; 2072-0505

Subject Terms: inflammatory bowel diseases, refractory Crohn's disease, hematopoietic stem cells, autologous hematopoietic stem cell transplantation, high-dose immunosuppressive therapy, воспалительные заболевания кишечника, рефрактерная болезнь Крона, стволовые клетки крови, аутологичная трансплантация гемопоэтических стволовых клеток, высокодозная иммуносупрессивная терапия

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/17387/1717; https://almclinmed.ru/jour/article/view/17387/1724; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160231; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160232; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160365; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160366; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160367; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160368; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160369; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160370; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160371; https://almclinmed.ru/jour/article/downloadSuppFile/17387/160372; https://almclinmed.ru/jour/article/view/17387

Availability: https://almclinmed.ru/jour/article/view/17387
https://doi.org/10.18786/2072-0505-2024-52-043

Hepatita autoimună în sarcină: prezentare de caz

Authors: Berliba, E.T., Vasilenco, I., Tcaciuc, E.M., Tofan-Scutaru, L.G.

Source: Sănătate Publică, Economie şi Management în Medicină 97_S (4) 132-137

Subject Terms: hepatită autoimună, autoimmune hepatitis, аутоиммунный гепатит, tratament imunosupresiv, anticorpi antinucleari, immunosuppressive treatment, antinuclear antibodies, иммуносупрессивная терапия, антинуклеарные антитела

File Description: application/pdf

Access URL: https://ibn.idsi.md/vizualizare_articol/194495

Predictors of Adverse Cardiovascular Events in Renal Transplant Recipients with Drugs Therapy During the Distant Postoperative Period

Source: Рецепт. :474-482

Subject Terms: obesity, дислипидемия, реципиент трансплантата почки, dyslipidemia, immunosuppressive therapy, кардиоваскулярные события, renal transplant recipient, 3. Good health, 03 medical and health sciences, cardiovascular events, 0302 clinical medicine, ожирение, NT-proBNP, erythrocytosis, эритроцитоз, иммуносупрессивная терапия

Успешный опыт лечения апластической анемии в Кыргызской Республике

Authors: Sagynali Mamatov, M.O. Eralieva, O.A. Dzhakypbaev, E.M. Sadabaev

Source: Клиническая онкогематология, Vol 13, Iss 4 (2020)

Subject Terms: апластическая анемия, антитимоцитарный глобулин, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, циклоспорин А, комбинированная иммуносупрессивная терапия, RC254-282, 3. Good health

Access URL: https://doaj.org/article/501b022fa9d643919cf1ec1d7b4811f5

State of protection against polio in children, who receive immunosuppressive therapy

Authors: A.M. Lisovska, A.P. Volokha, A.V. Bondarenko, T.V. Marushko, Yu.E. Golubovskaya

Source: Modern Pediatrics. Ukraine; № 3(107) (2020): Modern pediatrics. Ukraine; 29-32
Современная педиатрия. Украина; № 3(107) (2020): Современная педиатрия. Украина; 29-32
Сучасна педіатрія. Україна; № 3(107) (2020): Сучасна педіатрія. Україна; 29-32

Subject Terms: імуносупресивна терапія, вакцинація, діти, специфічні антитіла до вірусу поліомієліту, immunosuppressive therapy, vaccination, children, specific antibodies to poliovirus, 16. Peace & justice, иммуносупрессивная терапия, вакцинация, дети, специфические антитела к вирусу полиомиелита, 3. Good health

File Description: application/pdf

Access URL: https://med-expert.com.ua/journals/wp-content/uploads/2020/07/07.pdf
http://mpu.med-expert.com.ua/article/view/SP.2020.107.29

Predictive Models of seven-Year Patient survival after heart transplantation

Source: Кардиология в Беларуси. :88-98

Subject Terms: cell rejection reactions, 03 medical and health sciences, 0302 clinical medicine, terminal heart failure, внутрисосудистое ультразвуковое исследование, immunosuppressive therapy, orthotopic heart transplantation, терминальная сердечная недостаточность, ортотопическая трансплантация сердца, иммуносупрессивная терапия, 3. Good health, реакции клеточного отторжения, intravascular ultrasound

КЛИНИКО-ИММУНОЛОГИЧЕСКАЯ ХАРАКТЕРИСТИКА И ОЦЕНКА ПРЕДИКТОРОВ ЭФФЕКТИВНОСТИ ИММУНОСУПРЕССИВНОЙ ТЕРАПИИ У ПАЦИЕНТОВ С АУТОИММУННЫМ ГЕПАТИТОМ

Subject Terms: autoimmune hepatitis, аутоиммунный гепатит, оптимизация терапии, immunosuppressive therapy, optimization of therapy, liver, иммуносупрессивная терапия, клинико-иммунологическая диагностика

A 5-year single-center experience in heart transplantation in Rostov oblast ; Пятилетний опыт трансплантации сердца в Ростовской области

Authors: V. L. Korobka, M. Yu. Kostrykin, A. A. Duzhikov, V. D. Shamkhanyants, D. K. Lobachev, O. V. Kotov, A. A. Kartashov, A. V. Sumin, M. V. Gusnay, A. I. Trapeznikova, E. A. Kudryashova, R. V. Korobka, В. Л. Коробка, М. Ю. Кострыкин, А. А. Дюжиков, В. Д. Шамханьянц, Д. К. Лобачев, О. В. Котов, А. А. Карташов, А. В. Сумин, М. В. Гуснай, А. И. Трапезникова, Е. А. Кудряшова, Р. В. Коробка

Source: Russian Journal of Transplantology and Artificial Organs; Том 25, № 4 (2023); 96-101 ; Вестник трансплантологии и искусственных органов; Том 25, № 4 (2023); 96-101 ; 1995-1191

Subject Terms: иммуносупрессивная терапия, heart failure, immunosuppressive therapy, сердечная недостаточность

File Description: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/1675/1544; https://journal.transpl.ru/vtio/article/view/1675/1590; https://journal.transpl.ru/vtio/article/downloadSuppFile/1675/1394; https://journal.transpl.ru/vtio/article/downloadSuppFile/1675/1395; https://journal.transpl.ru/vtio/article/downloadSuppFile/1675/1396; https://journal.transpl.ru/vtio/article/downloadSuppFile/1675/1397; Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. JACC Heart Fail. 2020; 8 (7): 523–536.; Поляков ДС, Фомин ИВ, Беленков ЮН, Мареев ВЮ, Агеев ФТ, Артемьева ЕГ и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021; 61 (4): 414. https://doi.org/10.18087/cardio.2021.4.n1628.; Khush KK, Cherikh WS, Chambers DC, Goldfarb S, Hayes D Jr,, Kucheryavaya AY et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report – 2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018; 37 (10): 1155–1168.; Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK. Honoring 50 years of clinical heart transplantation in circulation: in-depth state-ofthe-art review. Circulation. 2018; 137 (1): 71–87.; Penninga L, Møller C, Gustafsson F, Steinbrüchel D, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol. 2010; 66: 1177–1187.; Kirk R, Edwards LB, Aurora P, Taylor DO, Christie J, Dobbels F et al. Registry of the International society for heart and lung transplantation: Eleventh official lung and heart/lung transplantation report – 2008. J Heart Lung Transplant. 2008; 27 (9): 978–983.; Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2021 году. XIV сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2022; 24 (3): 8–31. https://doi.org/10.15825/19951191-2022-3-8-31.; Клинические рекомендации МЗ РФ «Трансплантация сердца, наличие трансплантированного сердца, отмирание и отторжение трансплантата сердца», 2020 г.; Sarsam MA, Campbell CS, Yonasn NA, Deiraniya AK, Rahman AN. An alternative surgical technique in orthotopic cardiac transplatation. J Card Surg. 1993; 8: 344–349.; Готье СВ, Мойсюк ЯГ. Трансплантология. Фармакотерапия без ошибок. Руководство для врачей. М., 2014; 432.; Хубутия МШ, Соколов ВВ, Редкобородый АВ, Козлов ИА, Тимербаев ВХ, Хуцишвили ЛГ и др. Опыт 70 трансплантаций сердца в многопрофильном медицинском учреждении. Трансплантология. 2018; 10 (3): 197–206. https://doi.org/10.23873/2074-0506-2018-103-197-206.; https://journal.transpl.ru/vtio/article/view/1675

Availability: https://journal.transpl.ru/vtio/article/view/1675
https://doi.org/10.15825/1995-1191-2023-4-96-101

Features of the gut microbiota in children with chronic liver diseases ; Особенности кишечной микробиоты у детей с хроническими заболеваниями печени

Authors: G. V. Volynets, A. S. Potapov, A. V. Nikitin, L. G. Danilov, T. A. Skvortsova, V. V. Dudurich, Г. В. Волынец, А. С. Потапов, А. В. Никитин, Л. Г. Данилов, Т. А. Скворцова, В. В. Дудурич

Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 68, № 4 (2023); 66-76 ; Российский вестник перинатологии и педиатрии; Том 68, № 4 (2023); 66-76 ; 2500-2228 ; 1027-4065

Subject Terms: иммуносупрессивная терапия, intestinal microbiota, chronic liver disease, autoimmune liver disease, non-autoimmune liver disease, immunosuppressive therapy, кишечная микробиота, хронические болезни печени, аутоиммунные болезни печени, неаутоиммунные болезни печени

File Description: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/1850/1396; Mieli-Vergani G., Vergani D., Baumann U., Czubkowski P., Debray D., Dezsofi A. et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2018; 66(2): 345–360. DOI:10.1097/MPG.0000000000001801; Webb G.J., Hirschfield G.M., Krawitt E.L., Gershwin M.E. Cellular and Molecular Mechanisms of Autoimmune Hepatitis. Annu Rev Pathol 2018; 13: 247–292. DOI:10.1146/annurev-pathol-020117–043534; Mieli-Vergani G., Vergani D., Czaja A.J., Manns M.P., Krawitt E.L., Vierling J.M. et al. Autoimmune hepatitis. Nat Rev Dis Primers 2018; 4: 18017. DOI:10.1038/nrdp.2018.17; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63(4): 971–1004. DOI:10.1016/j.jhep.2015.06.030; Corrigan M., Hirschfield G.M., Oo Y.H., Adams D.H. Autoimmune hepatitis: an approach to disease understanding and management. Br Med Bull 2015; 114(1): 181–91. DOI:10.1093/bmb/ldv021; Manns M.P., Lohse A.W., Vergani D. Autoimmune hepatitis — Update 2015. J Hepatol 2015; 62(1 Suppl): S100–11. DOI:10.1016/j.jhep.2015.03.005; de Boer Y.S., van Gerven N.M., Zwiers A., Verwer B.J., van Hoek B., van Erpecum K.J. et al.; Dutch Autoimmune Hepatitis Study Group; LifeLines Cohort Study; Study of Health in Pomerania. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014; 147(2): 443–52.e5. DOI:10.1053/j.gastro.2014.04.022; Webb G.J., Hirschfield G.M. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun 2016; 66: 25–39. DOI:10.1016/j.jaut.2015.08.016; Adolph T.E., Grander C., Moschen A.R., Tilg H. Liver-Microbiome Axis in Health and Disease. Trends Immunol 2018; 39(9): 712–723. DOI:10.1016/j.it.2018.05.002; Kummen M., Holm K., Anmarkrud J.A., Nygård S., Vesterhus M., Høivik M.L. et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017; 66(4): 611–619. DOI:10.1136/gutjnl-2015–310500; Sabino J., Vieira-Silva S., Machiels K., Joossens M., Falony G., Ballet V. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65(10): 1681–1689. DOI:10.1136/gutjnl-2015–311004; Tang R., Wei Y., Li Y., Chen W., Chen H., Wang Q. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018; 67(3): 534–541. DOI:10.1136/gutjnl-2016–313332; Tripathi A., Debelius J., Brenner D.A., Karin M., Loomba R., Schnabl B. et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018; 15(7): 397–411. DOI:10.1038/s41575–018–0011-z; Yuksel M., Wang Y., Tai N., Peng J., Guo J., Beland K. et al. A novel «humanized mouse» model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 2015; 62(5): 1536–1550. DOI:10.1002/hep.27998; Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018; 359(6380): 1156–1161. DOI:10.1126/science.aar7201; Abe K., Takahashi A., Fujita M., Imaizumi H., Hayashi M., Okai K. et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 2018; 13(7): e0198757. DOI:10.1371/journal.pone.0198757; Lv L., Jiang H., Chen X., Wang Q., Wang K., Ye J. et al. The Salivary Microbiota of Patients With Primary Biliary Cholangitis Is Distinctive and Pathogenic. Front Immunol 2021; 12: 713647. DOI:10.3389/fimmu.2021.713647; He Y., Wu W., Zheng H.M., Li P., McDonald D., Sheng H.F. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med 2018; 24(10): 1532–1535. DOI:10.1038/s41591–018–0164-x; Huttenhower C., Gevers D., Knight R., Abubucker S., Badger J.H., Chinwalla A.T. et al. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402): 207–14. DOI:10.1038/nature11234; David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505(7484): 559–563. DOI:10.1038/nature12820; Sonnenburg E.D., Smits S.A., Tikhonov M., Higginbottom S.K., Wingreen N.S., Sonnenburg J.L. Diet-induced extinctions in the gut microbiota compound over generations. Nature 2016; 529(7585): 212–215. DOI:10.1038/nature16504; Modi S.R., Collins J.J., Relman D.A. Antibiotics and the gut microbiota. Clin Invest 2014; 124(10): 4212–4128. DOI:10.1172/JCI72333; Maurice C.F., Haiser H.J., Turnbaugh P.J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013; 152(1–2): 39–50. DOI:10.1016/j.cell.2012.10.052; Gabarre P., Loens C., Tamzali Y., Barrou B., Jaisser F., Tourret J. Immunosuppressive therapy after solid organ transplantation and the gut microbiota: Bidirectional interactions with clinical consequences. Am J Transplant 2022; 22(4): 1014–1030. DOI:10.1111/ajt.16836; Sonnenburg J.L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 535(7610): 56–64. DOI:10.1038/nature18846; Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J., Holmes S.P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 2016; 13(7): 581–583. DOI:10.1038/nmeth.3869; Wei Y., Li Y., Yan L., Sun C., Miao Q., Wang Q. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020; 69(3): 569–577. DOI:10.1136/gutjnl-2018–317836; Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 2013; 11: 639–647. DOI:10.1038/nrmicro3089; Imajo K., Fujita K., Yoneda M., Nozaki Y., Ogawa Y., Shinohara Y. et al. Hyperresponsivity tolow-dose endotoxin during progression to nonalcoholic steatohepatitis isregulated by leptin-mediated signaling. Cell Metab 2012; 16: 44–54. DOI:10.1016/j.cmet.2012.05.012; Gevers D., Kugathasan S., Denson L.A., Vázquez-Baeza Y., Van Treuren W., Ren B. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014; 15: 382–392. DOI:10.1016/j.chom.2014.02.005; Akberova D., Kiassov A.P., Abdulganieva D. Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases. J Immunol Res 2017; 2017: 9829436. DOI:10.1155/2017/9829436; Yoshida N., Emoto T., Yamashita T., Watanabe H., Hayashi T., Tabata T. et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation 2018; 138(22): 2486–2498. DOI:10.1161/CIRCULATIONAHA.118.033714; Koh A., De Vadder F., Kovatcheva-Datchary P., Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 2016; 165(6): 1332–1345. DOI:10.1016/j.cell.2016.05.041; Kriss M., Hazleton K.Z., Nusbacher N.M., Martin C.G., Lozupone C.A. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol 2018; 44: 34–40. DOI:10.1016/j.mib.2018.07.003; Kelly C.J., Zheng L., Campbell E.L., Saeedi B., Scholz C.C., Bayless A.J. et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe 2015; 17(5): 662–671. DOI:10.1016/j.chom.2015.03.005; Wu T., Yang L., Jiang J., Ni Y., Zhu J., Zheng X. et al. Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats. Life Sci 2018; 192: 173–182. DOI:10.1016/j.lfs.2017.11.049; Tourret J., Willing B.P., Dion S., MacPherson J., Denamur E., Finlay B.B. Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. Transplantation 2017; 101(1): 74–82. DOI:10.1097/TP.0000000000001492; He Z., Kong X., Shao T., Zhang Y., Wen C. Alterations of the Gut Microbiota Associated With Promoting Efficacy of Prednisone by Bromofuranone in MRL/lpr Mice. Front Microbiol 2019; 10: 978. DOI:10.3389/fmicb.2019.00978; Huang E.Y., Inoue T., Leone V.A., Dalal S., Touw K., Wang Y. et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis 2015; 21(5): 963–972. DOI:10.1097/MIB.0000000000000332; Steiner R.W., Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol 2011; 33(2): 157–167. DOI:10.1007/s00281–011–0259–7; Rodríguez-Piñeiro A.M., Johansson M.E. The colonic mucus protection depends on the microbiota. Gut Microbes 2015; 6(5): 326–330. DOI:10.1080/19490976.2015.1086057; Bunker J.J., Flynn T.M., Koval J.C., Shaw D.G., Meisel M., McDonald B.D. et al. Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. Immunity 2015; 43(3): 541–553. DOI:10.1016/j.immuni.2015.08.007; Sommer F., Anderson J.M., Bharti R., Raes J., Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol 2017; 15(10): 630–638. DOI:10.1038/nrmicro.2017.58; Kim H.B., Wang Y., Sun X. A Detrimental Role of Immunosuppressive Drug, Dexamethasone, During Clostridium difficile Infection in Association with a Gastrointestinal Microbial Shift. J Microbiol Biotechnol 2016; 26(3): 567–571. DOI:10.4014/jmb.1512.12017; Liu F., Ma R., Riordan S.M., Grimm M.C., Liu L., Wang Y. et al. Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes. Front Microbiol 2017; 8: 527. DOI:10.3389/fmicb.2017.00527; Swidsinski A., Loening-Baucke V., Bengmark S., Lochs H., Dörffel Y. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis 2007; 13(1): 51–56. DOI:10.1002/ibd.20003; Mousa O.Y., Juran B.D., McCauley B.M., Vesterhus M.N., Folseraas T., Turgeon C.T. et al. Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology 2021; 74(1): 281–295. DOI:10.1002/hep.31652; Watanabe Y., Nagai F, Morotomi M. Characterization of Phascolarctobacterium succinatutens sp. nov., an asaccharolytic, succinate-utilizing bacterium isolated from human feces. Appl Environ Microbiol 2012; 78(2): 511–518. DOI:10.1128/AEM.06035–11; Morgan X.C., Tickle T.L., Sokol H., Gevers D., Devaney K.L., Ward D.V. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13(9): R79. DOI:10.1186/gb-2012–13–9-r79; Horvath T.D., Ihekweazu F.D., Haidacher S.J., Ruan W., Engevik K.A., Fultz R. et al. Bacteroides ovatus colonization influences the abundance of intestinal short chain fatty acids and neurotransmitters. Science 2022; 25(5): 104158. DOI:10.1016/j.isci.2022.104158

Availability: https://www.ped-perinatology.ru/jour/article/view/1850
https://doi.org/10.21508/1027-4065-66-XX

Vaccination of pneumococcal infection in patients with systemic lupus erythe matosus and antiphospholipid syndrome: experience of 6 years of use ; Вакцинопрофилактика пневмококковой инфекции у пациентов с системной красной волчанкой и антифосфолипидным синдромом: опыт 6-летнего применения

Authors: G. M. Tarasova, B. S. Belov, T. M. Reshetnyak, M. V. Cherkasova, Г. М. Тарасова, Б. С. Белов, Т. М. Решетняк, М. В. Черкасова

Contributors: Статья подготовлена в рамках научно-исследовательских работ ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», № государственных заданий 1021051402790-6 и 1021051503137-7.

Source: Rheumatology Science and Practice; Vol 61, No 3 (2023); 330-338 ; Научно-практическая ревматология; Vol 61, No 3 (2023); 330-338 ; 1995-4492 ; 1995-4484

Subject Terms: иммуносупрессивная терапия, infections, systemic lupus erythematosus, antiphospholipid syndrome, immunosuppressive therapy, инфекции, системная красная волчанка, антифосфолипидный синдром

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3360/2288; Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005;38(7):473-485. doi:10.1080/08916930500285352; Dorgham DA, Anwar S, Khaled AS. Infection in systemic lupus erythematosus patients. The Egyptian Rheumatologist. 2021;43(2): 115-118. doi:10.1016/j.ejr.2020.12.007; Lu Z, Li J, Ji J, Gu Z, Da Z. Mortality prediction in systemic lupus erythematosus patients with pulmonary infection. Int J Rheum Dis. 2019;22(6):1077-1083. doi:10.1111/1756-185X.13555; Singh BK, Singh S. Systemic lupus erythematosus and infections. Reumatismo. 2020;72(3):154-169. doi:10.4081/reumatismo.2020.1303; García-Guevara G, Ríos-Corzo R, Díaz-Mora A, López-López M, Hernández-Flores J, Fragoso-Loyo H, et al. Pneumonia in patients with systemic lupus erythematosus: Epidemiology, microbiology and outcomes. Lupus. 2018;27(12):1953-1959. doi:10.1177/0961203318799207; Edwards CJ, Lian TY, Badsha H, The CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: Characteristics and predictors of outcome. Lupus. 2003;12(9):672-676. doi:10.1191/0961203303lu452oa; Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. doi:10.1093/ofid/ofu024; Luijten RK, Cuppen BV, Bijlsma JW, Derksen RH. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus. 2014;23(14):1512-1516. doi:10.1177/0961203314543918; Mykietiuk A, Carratalà J, Domínguez A, Manzur A, Fernández-Sabé N, Dorca J, et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with communityacquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006;25(7):457-462. doi:10.1007/s10096-006-0161-8; van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-422. doi:10.1136/ard.2010.137216; Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi:10.1136/annrheumdis-2019-215882; Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473; Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.; Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x; Teh CL, Ling GR. Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. Lupus. 2013;22(1):106-111. doi:10.1177/0961203312465780; Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: An updated meta-analysis. Lupus. 2016;25(7):727-734. doi:10.1177/0961203315627202; Moreno-Torres V, Martínez-Urbistondo M, Gutiérrez-Rojas A, Castejón R, Sánchez E, Calderón-Parra J, et al. Impact of severe infections in SLE: An observational study from the Spanish national registry. Lupus Sci Med. 2022;9(1):e000711. doi:10.1136/lupus2022-000711; Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515-532. doi:10.1038/s41584-021-00668-1; Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: Causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043-1053. doi:10.1080/1744666X.2018.1538789; Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: Susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286-1294. doi:10.1177/0961203313493032; Murdaca G, Orsi A, Spanò F, Faccio V, Puppo F, Durando P, et al. Vaccine-preventable infections in systemic lupus erythematosus. Hum Vaccin Immunother. 2016;12(3):632-643. doi:10.1080/21645515.2015.1107685; Chiganer EH, Ochi BC, Lessa CF. Influenza and pneumococcal vaccination coverage in Latin American patients with systemic lupus erythematosus: a cross-sectional and comparative study. Adv Rheumatol. 2021;61(1):46. doi:10.1186/s42358-021-00197-1; Mathian A, Arnaud L, Adoue D, Agard C, Bader-Meunier B, Baudouin V, et al.; le groupe France lupus érythémateux systémique réseau (FLEUR) et les centres de référence et de compétence des lupus et syndromes des antiphospholipides. Prévention des infections au cours du lupus systémique chez l’adulte et l’adolescent : élaboration de recommandations pour la pratique clinique, à partir d’une analyse de la littérature et de l’avis d’experts [Prevention of infections in adults and adolescents with systemic lupus erythematosus: Guidelines for the clinical practice based on the literature and expert opinion]. Rev Med Interne. 2016;37(5):307-320. doi:10.1016/j.revmed.2016.01.005; Millet A, Decaux O, Perlat A, Grosbois B, Jego P. Systemic lupus erythematosus and vaccination. Eur J Intern Med. 2009;20(3):236-241. doi:10.1016/j.ejim.2008.07.017; Nguyen M, Lindegaard H, Hendricks O, Friis-Mоller N. Factors associatedwith influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol. 2017;46(6):446-453. doi:10.1080/03009742.2016.1242774; Loubet P, Kernéis S, Groh M, Loulergue P, Blanche P, Verger P, et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015;33(31):3703-3708. doi:10.1016/j.vaccine.2015.06.012; Subesinghe S, Rutherford AI, Ibrahim F, Harris H, Galloway J. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. doi:10.1186/s12891-016-1187-4; Наумцева МС, Белов БС, Александрова ЕН, Тарасова ГМ, Новиков АА, Каратеев ДЕ, и др. Иммуногенность и безопасность 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом: результаты двухлетнего наблюдения. Научно-практическая ревматология. 2016;54(6):674-680. doi:10.14412/1995-4484-2016-674-680; Bukhanova D, Sergeeva M, Belov B, Tarasova G, Cherkasova MV, Muraviev Y, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in RA patients: Results of a 4-year follow up study. Ann Rheum Dis. 2018;77(Suppl 2):1060. doi:10.1136/annrheumdis-2018-eular.1586; Bukhanova D, Belov B, Tarasova G, Sergeeva M, Muravyev Y, Lukina G, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: Results from 5-year follow up. Ann Rheum Dis. 2019;78(Suppl 2):336. doi:10.1136/annrheumdis-2019-eular.3173; Tarasova G, Belov B, Bukhanova D, Cherkasova M, Solovyev S, Aseeva E, et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: The relationship of immunogenicity with therapy. Ann Rheum Dis. 2019;78(Suppl 2): 785-786. doi:10.1136/annrheumdis-2019-eular.3646; Adawi M, Bragazzi NL, McGonagle D, Watad S, Mahroum N, Damiani G, et al. Immunogenicity, safety and tolerability of antipneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmun Rev. 2019;18(1):73-92. doi:10.1016/j.autrev.2018.08.002; Pugès M, Biscay P, Barnetche T, Truchetet MÉ, Richez C, Seneschal J, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: A systematic literature review and meta-analysis. Rheumatology (Oxford). 2016;55(9):1664-1672. doi:10.1093/rheumatology/kew211; Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159. doi:10.4414/smw.2015.14159; Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002;34(2):147-153. doi:10.1086/338043; Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016-1026. doi:10.1002/acr.22246; Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171. doi:10.1186/ar4358; Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood. 2006;108(6):1975-1978. doi:10.1182/blood-2006-04-014639; Steiger S, Ehreiser L, Anders J, Anders HJ. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front Immunol. 2022;13:999704. doi:10.3389/fimmu.2022.999704; Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055-1065. doi:10.1128/CVI.00131-10; Chehab G, Richter JG, Brinks R, Fischer-Betz R, Winkler-Rohlfing B, Schneider M. Vaccination coverage in systemic lupus erythematosus-a cross-sectional analysis of the German long-term study (LuLa cohort). Rheumatology (Oxford). 2018;57(8):1439-1447. doi:10.1093/rheumatology/key120; Sulis G, Rodrigue V, Wolfson C, McMillan JM, Kirkland SA, Andrew MK, et al. Pneumococcal vaccination uptake and missed opportunities for vaccination among Canadian adults: A cross-sectional analysis of the Canadian Longitudinal Study on Aging (CLSA). PLoS One. 2022;17(10):e0275923. doi:10.1371/journal.pone.0275923; Peng L, Wang Y, Zhao L, Chen T, Huang A. Severe pneumonia in Chinese patients with systemic lupus erythematosus. Lupus. 2020;29(7):735-742. doi:10.1177/0961203320922609

Availability: https://rsp.mediar-press.net/rsp/article/view/3360
https://doi.org/10.47360/1995-4484-2023-330-338

Clinical manifestations and prognosis of giant cell arteritis: A retrospective cohort study ; Клинические проявления и прогноз гигантоклеточного артериита: ретроспективное когортное исследование

Authors: E. E. Filatova, N. M. Bulanov, A. D. Meshkov, O. O. Borodin, I. O. Smitienko, E. V. Chachilo, A. A. Nartov, A. L. Filatova, A. V. Naumov, P. I. Novikov, S. V. Moiseev, Е. Е. Филатова, Н. М. Буланов, А. Д. Мешков, О. О. Бородин, И. О. Смитиенко, Е. В. Чачило, А. А. Нартов, А. Л. Филатова, А. В. Наумов, П. И. Новиков, С. В. Моисеев

Source: Rheumatology Science and Practice; Vol 61, No 6 (2023); 735-743 ; Научно-практическая ревматология; Vol 61, No 6 (2023); 735-743 ; 1995-4492 ; 1995-4484

Subject Terms: иммуносупрессивная терапия, polymyalgia rheumatica, ultrasound, survival, immunosuppressive therapy, ревматическая полимиалгия, УЗДГ, выживаемость

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3473/2333; Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: A systematic review. JAMA. 2016;315(22):2442-2458. doi:10.1001/jama.2016.5444; Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med. 2003;349(2):160-169. doi:10.1056/NEJMra022694; Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50-57. doi:10.1056/NEJMcp1214825; Мешков АД, Новиков ПИ, Фомин ВВ, Моисеев СВ. Гигантоклеточный артериит: трудности диагностики и методы лечения. Клиническая фармакология и терапия. 2014;23(2):48-54.; Сатыбалдыев АМ. Гигантоклеточный артериит. Часть I. Терминология, классификация, клинические проявления, диагностика. Современная ревматология. 2012;(3):23-27. doi: 14412/1996-7012-2012-741; Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;48:73-75. doi:10.1016/j.jaut.2014.01.017; Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633-639. doi:10.1002/art.30155; Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: Revisiting the concept of the disease. Rheumatology. 2017;56(4):506-515. doi: 1093/rheumatology/kew273; Wigley RD, Zhang NZ, Zeng QY, Shi CS, Hu DW, Couchman K, et al. Rheumatic diseases in China: ILAR-China study comparing the prevalence of rheumatic symptoms in northern and southern rural populations. J Rheumatol. 1994;21(8):1484-1490.; Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum Off J Am Coll Rheumatol. 1983;26(10):1214-1219. doi:10.1002/art.1780261007; Мешков АД, Маслянский АЛ, Ткачева ОН, Мазуров ВИ. Лечение гигантоклеточного артериита: современные возможности и перспективы стероид-сберегающей терапии. Терапия. 2023;1(9):78-88. doi:10.18565/therapy.2023.1.78-88; Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100(4):550-555. doi:10.1016/s0161-6420(93)31608-8; Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: Diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32(3):259. doi:10.1097/WNO.0b013e318268aa9b; Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018;57(2):322-328. doi:10.1093/rheumatology/kex397; Мухин НА, Мешков АД, Новиков ПИ, Моисеев СВ, Щербакова ВД, Манукова ВА, и др. Гигантоклеточный артериит: клинические проявления и методы ранней диагностики. Клиническая фармакология и терапия. 2015;24(3):79-85.; de Boysson H, Liozon E, Ly KH, Dumont A, Delmas C, Aouba A. The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol. 2019;37(Suppl 117(2)):57-60.; Gajree S, Borooah S, Dhillon N, Goudie C, Smith C, Aspinall P, et al. Temporal artery biopsies in south-east Scotland: A five year review. J R Coll Physicians Edinb. 2017;47(2):124-128. doi:10.4997/JRCPE.2017.203; Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603-606. doi:10.1007/s10157-013-0869-6; Новиков ПИ, Семенкова ЕН, Моисеев СВ. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013;22(1):70-74.; Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989-1994. doi:10.1136/annrheumdis-2012-202408; Breuer GS, Poltorak V, Nesher G. Survival of patients with giant cell arteritis: A controversial issue. Clin Exp Rheumatol. 2020;38(Suppl 124):210-213.; Schmidt J, Smail A, Roche B, Gay P, Salle V, Pellet H, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: A multicenter, prospective, double-cohort study. Arthritis Rheumatol. 2016;68(6):1477-1482. doi:10.1002/art.39596; Mollan SP, Begaj I, Mackie S, O’Sullivan EP, Denniston AK. Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002–13, without a decrease in associated sight loss: Potential implications for service provision. Rheumatology. 2015;54(2):375-377. doi:10.1093/rheumatology/keu433; Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128. doi:10.1002/art.1780330810; Salehi-Abari I. 2016 ACR revised criteria for early diagnosis of giant cell (temporal) arteritis. Autoimmune Dis Ther Approaches Open Access. 2016;3:1-4.; Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81(12):1647-1653. doi:10.1136/ard-2022-223480; Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/ American College of Rheumatology collaborative initiative. 2012;64:943-954. doi:10.1002/art.34356; Bland JM, Altman DG. Survival probabilities (the Kaplan – Meier method). BMJ. 1998;317:1572-1580. doi:10.1136/bmj.317.7172.1572; Majerovich K, Junek M, Khalidi N, Garner S. Duration of steroid therapy and temporal artery biopsy positivity in giant cell arteritis: A retrospective cohort study. J Rheumatol. 2023;50(7):965-966. doi:10.3899/jrheum.220860; Dagostin MA, Pereira RMR. Giant cell arteritis: Current advances in pathogenesis and treatment. Rijeka:IntechOpen;2020. doi:10.5772/intechopen.91018; Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013;381(9860):63-72. doi:10.1016/S0140-6736(12)60680-1; Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C, et al. Fast track pathway reduces sight loss in giant cell arteritis: Results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S103-S106.; Ninet JP, Bachet P, Dumontet CM, Du Colombier PB, Stewart MD, Pasquier JH. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med. 1990;88(1):13-20. doi:10.1016/0002-9343(90)90121-s; Berti A, Campochiaro C, Cavalli G, Pepe G, Praderio L, Sabbadini MG, et al. Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. Autoimmun Rev. 2015;14(4):352-357. doi:10.1016/j.autrev.2014.12.005; Alba MA, García-Martínez A, Prieto-González S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: Prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194-201. doi:10.1097/MD.0000000000000033; Murchison AP, Gilbert ME, Bilyk JR, Eagle RC Jr, Pueyo V, Sergott RC, et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154(4):722-729. doi:10.1016/j.ajo.2012.03.045; Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-1597. doi:10.1093/rheumatology/keq039a; Moiseev SV, Smitienko I, Bulanov N, Novikov PI. The role of temporal artery biopsy in patients with giant-cell arteritis is debated. Ann Rheum Dis. 2019;78(4):e31. doi:10.1136/annrheumdis-2018-213282; Schäfer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology. 2017;56(9):1479-1483. doi:10.1093/rheumatology/kex143; Филатова ЕЕ, Буланов НМ, Мешков АД, Бородин ОО, Смитиенко ОИ, Чачило ЕВ, и др. Поражение экстракраниальных артерий при гигантоклеточном артериите по данным позитронно-эмиссионной и компьютерной томографии. Научно-практическая ревматология. 2023;61(1):106-111. doi:10.47360/1995-4484-2023-106-111; Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica – A prospective study of 99 patients. Rheumatology. 2018;57(11):1908-1916. doi:10.1093/rheumatology/kex376; de Boysson H, Lambert M, Liozon E, Boutemy J, Maigné G, Ollivier Y, et al. Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern. Medicine (Baltimore). 2016;95(26):e3818. doi:10.1097/MD.0000000000003818; Malich L, Gühne F, Hoffmann T, Malich A, Weise T, Oelzner P, et al. Distribution patterns of arterial affection and the influence of glucocorticoids on 18F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis. RMD Open. 2022;8(2):e002464. doi:10.1136/rmdopen-2022-002464; Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns of arterial disease in Takayasu arteritis and giant cell arteritis. Arthritis Care Res (Hoboken). 2020;72(11):1615-1624. doi:10.1002/acr.24055; Förster S, Tato F, Weiss M, Czihal M, Rominger A, Bartenstein P, et al. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. Vasa. 2011;40(3):219-227. doi:10.1024/0301-1526/a000096; Nielsen BD, Hansen IT, Kramer S, Haraldsen A, Hjorthaug K, Bogsrud TV, et al. Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: A case-control study. Eur J Nucl Med Mol Imaging. 2019;46(1):184-193. doi:10.1007/s00259-018-4106-0; Rottenburger C, Mensch N, Imfeld S, Aschwanden M, Glatz K, Staub D, et al. 18F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches. Swiss Med Wkly. 2021;151:w20512. doi:10.4414/smw.2021.20512; Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. doi:10.1136/annrheumdis-2019-215672; Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. doi:10.1002/art.41774; Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: Current challenges and opportunities. Nat Rev Rheumatol. 2017;13(10):578-592. doi:10.1038/nrrheum.2017.142; Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal cohort study. J Rheumatol. 2015;42(7):1213-1217. doi:10.3899/jrheum.141347; Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2023:ard-2022-223429. doi:10.1136/ard-2022-223429; Lavergne A, Dumont A, Deshayes S, Boutemy J, Maigné G, Silva NM, et al. Efficacy and tolerance of methotrexate in a reallife monocentric cohort of patients with giant cell arteritis. Semin Arthritis Rheum. 2023;60:152192. doi:10.1016/j.semarthrit.2023.152192; Dumont A, Parienti JJ, Delmas C, Boutemy J, Maigné G, Martin Silva N, et al. Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J Rheumatol. 2020;47(1):108-116. doi:10.3899/jrheum.181127; Vautier M, Dupont A, de Boysson H, Comarmond C, Mirault T, Mekinian A, et al. Prognosis of large vessel involvement in large vessel vasculitis. J Autoimmun. 2020;108:102419. doi:10.1016/j.jaut.2020.102419; Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A, et al. Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res (Hoboken). 2017;69(3):430-438. doi:10.1002/acr.22942; Garen T, Lerang K, Hoffmann-Vold AM, Andersson H, Midtvedt Ø, Brunborg C, et al. Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides. Rheumatology (Oxford). 2019;58(2):313-320. doi:10.1093/rheumatology/key285; Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV, Lester S. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):513-519. doi:10.1016/j.semarthrit.2016.08.015

Availability: https://rsp.mediar-press.net/rsp/article/view/3473
https://doi.org/10.47360/1995-4484-2023-735-743